Working… Menu

Efficacy Study of CYT997 in Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00664378
Recruitment Status : Terminated (Difficulty enrolling patients)
First Posted : April 22, 2008
Last Update Posted : June 8, 2018
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:
This is a clinical research study that is designed to test the safety of CYT997 when given to patients with multiple myeloma and to test if CYT997 has any activity against that cancer.

Condition or disease Intervention/treatment Phase
Relapsed and Refractory Multiple Myeloma Drug: CYT997 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Single-arm, Two-stage, Open-label Phase II Trial of CYT997 in Relapsed and Refractory Multiple Myeloma
Study Start Date : January 2008
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: I
Drug: CYT997
Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle

Primary Outcome Measures :
  1. Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma [ Time Frame: Baseline to study completion ]
    The overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma once every 3 week cycle

Secondary Outcome Measures :
  1. Number of cycles required to achieve maximum response [ Time Frame: Baseline to study completion ]
  2. Overall survival [ Time Frame: Baseline to study completion ]
  3. Safety and tolerability [ Time Frame: Baseline to study completion ]
  4. Time to disease progression [ Time Frame: Baseline to study completion ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of multiple myeloma per International Working Group (IWG) criteria
  • Have received at least 1 but no more than 4 prior lines of therapy
  • Have failed to respond to the most recently administered anti-myeloma therapy
  • Have a life expectancy of at least 3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status < 3
  • At registration absolute neutrophil count > 1x10^9/L and platelet count > 50 x 10^9/L unsupported
  • At registration bilirubin less than 1.5 x upper limit of normal and transaminases less than 2 x upper limit of normal and serum creatinine less than 0.19 mmol/L
  • Written informed consent
  • Must agree to adequate contraceptive measure if indicated

Exclusion Criteria:

  • Patients with monoclonal gammopathy of undetermined significance
  • Known or suspected hypersensitivity to CYT997
  • Patient with uncontrolled intercurrent illness
  • Active infections or other illnesses that precludes chemotherapy administration or patient compliance.
  • Pregnant or lactating women.
  • Patients who have received any other investigational agents in the last 3 weeks prior to the start of treatment.
  • Patients with the following conditions will be excluded:

    • myocardial infarction or stroke within 6 months
    • unstable angina pectoris or acute ischemic changes on ECG
    • history of diabetic retinopathy
    • symptomatic peripheral arterial disease
    • major surgery in the last 30 days
  • Patients with uncontrolled diarrhea despite optimal medication and those with any history of acute gastrointestinal bleeding
  • Patients with a baseline prolongation of the QTc interval of Common Terminology Criteria (CTC) Grade 1 (QTc > 0.45-0.47 sec) or greater
  • Patients with impaired cardiac function or clinically significant cardiac diseases, including any one of the following:

    • left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiogram;
    • complete left bundle branch block;
    • obligate use of a cardiac pacemaker;
    • congenital long QT syndrome;
    • history or presence of ventricular tachyarrhythmia;
    • presence of unstable atrial fibrillation (ventricular response > 100 bpm). -Patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria;
    • clinically significant resting bradycardia (< 50 bpm);
    • right bundle branch block + left anterior hemiblock (bifascicular block);
    • angina pectoris ≤ 3 months prior to starting study drug;
    • acute myocardial infarction (MI) ≤ 3 months prior to starting study drug; or
    • other clinically significant heart disease (e.g., congestive heart failure (CHF), uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).
  • Patients currently receiving treatment with medications known to prolong the QTc interval and/or to induce Torsades de Pointes arrhythmia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00664378

Layout table for location information
Australia, Victoria
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Gilead Sciences
Layout table for investigator information
Principal Investigator: Andrew Spencer, Assoc Prof. Myeloma Research Group, The Alfred Hospital, Melbourne
Layout table for additonal information
Responsible Party: Gilead Sciences Identifier: NCT00664378    
Other Study ID Numbers: CCL07001
First Posted: April 22, 2008    Key Record Dates
Last Update Posted: June 8, 2018
Last Verified: April 2013
Keywords provided by Gilead Sciences:
Multiple myeloma, relapsed, refractory
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases